Active Ingredient History
Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. It is FDA approved for the treatment of tuberculosis, meningococcal carrier state. Healthy subjects who received rifampin 600 mg once daily concomitantly with saquinavir 1000 mg/ritonavir 100 mg twice daily (ritonavir-boosted saquinavir) developed severe hepatocellular toxicity. Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. Common adverse reactions include heartburn, epigastric distress, anorexia, nausea, vomiting, jaundice, flatulence, cramps. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominal Injuries (Phase 3)
Acquired Immunodeficiency Syndrome (Phase 4)
Alzheimer Disease (Phase 3)
Amputation, Surgical (Phase 4)
Analgesics, Opioid (Phase 1)
Anesthesia (Phase 1)
Arsenic Trioxide (Phase 4)
Arthritis, Reactive (Phase 3)
Arthritis, Rheumatoid (Phase 1)
Autoimmune Diseases (Phase 1)
Bacterial Infections (Phase 3)
Biological Availability (Phase 1)
Blood-Borne Infections (Phase 3)
Blood Glucose (Phase 4)
Blood Pressure (Phase 4)
Carcinoma (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Renal Cell (Phase 1)
Clinical Trial (Phase 1/Phase 2)
Conscious Sedation (Phase 1)
Constipation (Phase 1)
Contraception (Phase 4)
Coronary Artery Disease (Phase 1)
COVID-19 (Phase 1)
Cystic Fibrosis (Phase 4)
Dermatology (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diarrhea (Phase 3)
Drug Interactions (Phase 4)
Endocarditis (Phase 4)
Endometriosis (Phase 1)
Enterocolitis, Pseudomembranous (Phase 3)
Erectile Dysfunction (Phase 1)
Essential Hypertension (Phase 1)
Exocrine Pancreatic Insufficiency (Phase 1)
Fibrosis (Phase 1)
Gastrointestinal Hormones (Phase 1)
Genetic Diseases, Inborn (Phase 2)
Healthcare-Associated Pneumonia (Phase 3)
Healthy Volunteers (Phase 4)
Hematologic Neoplasms (Phase 1)
Hepatitis (Phase 4)
Hepatitis B, Chronic (Phase 1)
Hepatitis C (Phase 1)
HIV (Phase 3)
HIV Infections (Phase 4)
Hodgkin Disease (Phase 1)
Hypercalcemia (Phase 2)
Hypercalciuria (Phase 2)
Hyperlipidemias (Phase 1)
Infections (Phase 4)
Kidney Transplantation (Phase 4)
Latent Tuberculosis (Phase 4)
Leprosy (Phase 4)
Leukemia (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Lung Diseases (Phase 4)
Lymphoma (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Large-Cell, Anaplastic (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Medical Oncology (Phase 1)
Melanoma (Phase 1)
Mesothelioma (Phase 1)
Metabolic Detoxication, Phase I (Phase 1)
Metabolism (Phase 4)
Multiple Myeloma (Phase 1)
Multiple Sclerosis (Phase 2)
Multiple System Atrophy (Phase 3)
Mycobacterium avium Complex (Phase 4)
Mycobacterium Infections, Nontuberculous (Phase 4)
Mycoses (Phase 1)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 1)
Nocturia (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 4)
Onchocerciasis (Phase 2)
Osteomyelitis (Phase 4)
Pain (Phase 1)
Parkinson Disease (Phase 1)
Pericarditis, Tuberculous (Phase 2)
Pharmacokinetics (Phase 1)
Pneumonia, Ventilator-Associated (Phase 3)
Primary Myelofibrosis (Phase 1)
Prosthesis-Related Infections (Phase 4)
Pulmonary Arterial Hypertension (Phase 1)
Renal Insufficiency (Phase 4)
Renal Insufficiency, Chronic (Phase 2)
Respiratory Syncytial Virus Infections (Phase 1)
Respiratory Tract Infections (Phase 4)
Rhabdoid Tumor (Phase 1)
Rhabdomyosarcoma (Phase 2)
Rhinoscleroma (Phase 1)
Rifampin (Phase 1)
Sarcoidosis (Phase 2)
Sarcoidosis, Pulmonary (Phase 1)
Sarcoma (Phase 1)
Sarcoma, Synovial (Phase 1)
Staphylococcal Infections (Phase 4)
Staphylococcus aureus (Phase 4)
Thrombosis (Phase 1)
Tuberculosis ()
Tuberculosis, Meningeal (Phase 3)
Tuberculosis, Multidrug-Resistant (Phase 2)
Tuberculosis, Spinal (Phase 4)
Uveitis, Anterior (Phase 3)
Women (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
